Mitchell Bloom is Global Chair of Goodwin’s Life Sciences practice. Mr. Bloom specializes in representing public and private life science companies, as well as venture capital firms and investment banks focused on the life sciences sector.
Mr. Bloom's practice is focused on the representation of emerging and public life science companies, and he serves as principal outside or general counsel to leading life science companies. In addition to day-to-day corporate counseling and strategic advice to his clients, he regularly handles a variety of major business transactions, including public offerings, mergers and acquisitions, venture capital financings and strategic commercial transactions.
Mr. Bloom’s representative clients include, among others: Akero Therapeutics; Alkermes; Alnylam Pharmaceuticals; Aptinyx; Atlas Venture; BeiGene; Black Diamond Therapeutics; BridgeBio; Cabaletta; Casma Therapeutics; Centessa Pharmaceuticals; Compass Pathways; Coridea; Cullinan Oncology; ElevateBio; Esperion Therapeutics; Eventide; Faze Medicines; Fusion Pharmaceuticals; Gate Therapeutics; Gemini Therapeutics; Global Blood Therapeutics; Graphite Bio; iTeos Therapeutics; Karuna Therapeutics; MBX Biosciences; MPM Capital; Nimbus Therapeutics; ProQR Therapeutics; PureTech Health; Relay Therapeutics; Rheos Medicines; Tango Therapeutics; TCR2 Therapeutics; Third Rock Ventures; Vericel Corporation and Versant Ventures.
Mr. Bloom is a member of the American, Massachusetts and Boston Bar Associations.
Prior to joining Goodwin, Mr. Bloom was a partner at Testa, Hurwitz & Thibeault in Boston, where he was a member of the Business Practice Group and co-chair of its Life Sciences Practice.
Mr. Bloom is recognized nationally for his leadership in the life sciences industry and has been included in numerous legal guides for his corporate finance and life sciences expertise, including Chambers USA: America’s Leading Lawyers for Business, Chambers Global, U.S. News-Best Lawyers and The Legal 500 United States. In addition, for the past two years he has been selected as a “Life Science Star” by LMG Life Sciences.
Mr. Bloom is one of the leading life science capital markets lawyers in the U.S. and is the country’s most active attorney representing issuer-side life science IPOs since 2017.
Under his leadership, Goodwin’s Life Sciences practice has received numerous awards and honors, including U.S. News’Biotechnology Law Firm of the Year numerous times and perennial nationwide recognition by Chambers USA, among other legal guides.
(cum laude)
Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.
Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.
客户信赖我们世界一流的咨询服务，希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题，涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息，请与我们联系。